Bibliography
  1. Robert G et al. “Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have. Nonvalvular Atrial Fibrillation” J Am Coll Cardiol 2017;70,2964-75
  2. Ruff CT et al. “Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomized trials” Lancet 2014;338:955-62
  3. Bungard TJ et al. “Why do patients with atrial fibrillation not receive warfarin?” Arch intern Med 2000;160:41-6
  4. Marcus F et al. “Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: A transesophageal echocardiographic study” JACC 1995:452-9
  5. Reddy VY et al. “5-Years outcomes after left atrial appendage closure forme the PREVAIL and PROTECT AF trials” JACC 2017;70(24):2964-2975
  6. Saw J et al. “Early Canadian Multicenter Experience With Watchamn for Percutaneous Left Atrial Appendage Closure” J Cardiovasc Electrophysiol 2017 Apr;28(4):396-401
  7. Gianni C et al. “Closure of the left atrial appendage using percutaneous transcatheter occlusion devices” J Cardiovasc Electrophysiol 2020 Aug;31(8):2179-2186
  8. Gasperetti A et al. “A left atrial appendage closure combined procedure review: Past, present and future perspectives” J Cardiovasc Electrophysiol 2019;30(8):1345-1351
  9. Phillips KP et al. “Combining Watchman left atrial appendage closure and catheter ablation for atrial fibrillation: multicentre registry results of feasibility and safety during implant and 30 days follow-up” Europace 2018;20(6):949-955
  10. Kawakami H et al. “Cost-effectiveness of combined catheter ablation and left atrial appendage closure for symptomatic atrial fibrillation in patients with high stroke and bleeding risk” Am Heart J 2021;231:110-120
  11. Jiantao Y et al. “Long-term safety and efficacy of combined percutaneous LAA and PFO/ASD closure: a single-center experience” Expert Rev Devices 2019;16(5):429-435
  12. Zhang ZH et al. “One-stop shop: Safety and efficacy of combining atrial septal defect occlusion and left atrial appendage closure for patients with atrial septal defect and atrial fibrillation” BMC Cardiovasc Disord. 2020;20(1):444
  13. Reynolds D et al. “Micra Transcatheter Pacing Study Group. A leadless intra- cardiac transcatheter pacing system” N Engl J Med 2016;374:533-541.
  14. Regoli F. et al. “Combined left atrial appendage closure and pacemaker implant through a single right femoral vein access” Pacing Clin Electrophysiol 2016;39:900-902.
  15. Regoli F et al. “Potential Clinical Utility and Feasibility of Combined Left Atrial Appendage Closure and Positioning of Miniaturized Pacemaker Through a Single Right Femoral Vein Access” Am J Cardiol 2017;120:236-242
  16. Kleinecke C et al. “Amplatzer left atrial appendage closure: Single versus combined procedures” Catheter cardiovasc interv. 2020 10.1002/ccd.29271
  17. Tzikas A et al. “Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints, and collection requirements for clinical studies” Europace 2017;(19)4-15:10.1093
  18. Holmes DR et al., for the PROTECT AF Investigators. “Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial” Lancet 2009;374: 534–4
  19. Schulman, S. et al. “Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients” Journal of Thrombosis and Haemostasis 3(4), 692–694.
  20. Mehran, R. et al. “Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium” Circulation, 123(23), 2736–2747.
  21. Sacco, R. L. et al. “Council on Nutrition, Physical Activity and Metabolism. (2013). An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association” Stroke, 44(7), 2064–2089.
  22. Michael Glikson et al. ”EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion – an update” EuroIntervention. 2020 Jan 17;15(13):1133-1180
  23. Holmes Jr DR et al. ”Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial” J Am Coll Cardiol 2014 16;64(11):1186
  24. Alison Cooper et al. ”Sources of unsafe primary care for older adults: a mixed-methods analysis of patient safety incident reports” Age Ageing. 2017 Sep 1;46(5):833-839.
  25. John E. Morley, MB et al. “Frailty Consensus: A Call to Action” J Am Med Dir Assoc. 2013 Jun; 14(6): 392–397.
  26. Jeremy Walston et al. ”Frailty Screening and Interventions: Considerations for Clinical Practice” Clin Geriatr Med. 2018 Feb;34(1):25-38
  27. Louis Labrousse et al. ”Guidance of the MitraClip ® procedure by 2D and 3D imaging” Arch Cardiovasc Dis. Jun-Jul 2018;111(6-7):432-440.
  28. Turagam MK et al. ”Intracardiac echocardiography-guided implantation of the Watchman FLX left atrial appendage closure device” J Cardiovasc Electrophysiol. 2021 Mar;32(3):717-725.
  29. Gianni C at al. ”Intracardiac echocardiography- versus transesophageal echocardiography-guided left atrial appendage occlusion with Watchman FLX” J Cardiovasc Electrophysiol. 2021 Oct;32(10):2781-2784.
  30. John Fanourgiakis et al. ”Cost-of-illness study of patients subjected to cardiac rhythm management devices implantation: results from a single tertiary centre” Europace. 2013 Mar;15(3):366-75.
  31. Clifford J. Kavinsky et al. ”SCAI/ACC/HRS Institutional and Operator Requirements for Left Atrial Appendage Occlusion” J Am Coll Cardiol. 2016 May 17;67(19):2295-2305.